Regulatory Strategy
Phact supported a start-up company in outlining a regulatory strategy that was planned to be discussed with the EMA’s multidisciplinary expert team, the Innovative Task Force, ITF).
A start-up company is confronted with the following situations:
- Lack of knowledge about regulatory requirements for advanced therapy medicinal products (ATMPs)
- Disagreement between different departments on how to proceed with product and process development
- Non-routine manufacturing process
- Lack of experience with authority meetings
Knowledge
Lack of knowlege about
regulatory requirements for ATMPs
Experience
Lack of experience with authority meetings
Strategy
Missing regulatory strategy
How to Proceed?
The question is – what next steps should be taken in ATMP development? The solution is to draw up regulatory strategy for the specific product and discuss it with the EMA’s Innovative Task Force team.
The following measures are taken
- Application for a briefing meeting at EMA / Innovative Task Force (ITF)
- Preparing the briefing documentation
- Training of staff in preparation of the briefing meeting
- Presentation of the envisaged regulatory strategy
- Evaluation of the meeting outcome and initiating the next steps
Loading
Your form has been submitted
Thank you %NAME% for taking the quiz/survey/feedback.
We have received your answers. You can view it anytime from this link below:
%TRACK_LINK%
We have also attached a copy of your submission.
Server Side Error
We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.
If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.
TextStatus: undefined
HTTP Error: undefined
Processing your request
Error
Some error has occured.